Patients with ERα-negative breast cancer are more sensitive to anthracyclines-based neoadjuvant chemotherapy than ERα-positive patients (Liedtke et al., 2008), but the mechanism behind this response remains uncleared. The gene discussed is ESR1; the disease is breast carcinoma.